company background image
BDX logo

Becton Dickinson NYSE:BDX Stock Report

Last Price

US$241.24

Market Cap

US$69.8b

7D

-1.7%

1Y

3.9%

Updated

28 Feb, 2024

Data

Company Financials +

Becton, Dickinson and Company

NYSE:BDX Stock Report

Market Cap: US$69.8b

BDX Stock Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

BDX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance1/6
Financial Health4/6
Dividends5/6

Becton, Dickinson and Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Becton Dickinson
Historical stock prices
Current Share PriceUS$241.24
52 Week HighUS$287.32
52 Week LowUS$228.62
Beta0.45
1 Month Change1.43%
3 Month Change2.14%
1 Year Change3.91%
3 Year Change-0.17%
5 Year Change-2.95%
Change since IPO9,309.54%

Recent News & Updates

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08
Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 03
Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Recent updates

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08
Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 03
Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

Jan 22

Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 30
Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24

Nov 13

Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Nov 12
Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

Nov 06
Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Oct 05
With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Becton, Dickinson Stock Is A Hold, Here's Why

Oct 04

Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers

Aug 30

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Aug 13
We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Jul 28
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Jun 22
Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Becton, Dickinson and Company: Still Not Very Healthy

Jun 20

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Jun 08

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Apr 22
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Mar 20
Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Mar 05
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use

Feb 21

Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test

Feb 08

Becton, Dickinson Q1 2023 Earnings Preview

Feb 01

Becton, Dickinson declares $0.91 dividend

Jan 24

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Jan 09
We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod

Jan 09

Becton, Dickinson: A Quality Defensive Pick For 2023

Dec 20

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Dec 01
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91

Nov 13
Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91

Becton, Dickinson Q4 2022 Earnings Preview

Nov 09

Becton, Dickinson, Biocorp team up for traceability of injectable drugs

Oct 18

Becton, Dickinson: Buy In Now While You Can

Oct 12

Does Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?

Oct 05
Does Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?

BD, Certest Biotec launch monkeypox test

Sep 26

Becton, Dickinson launches next-gen prefillable vaccine syringe BD Effivax

Sep 13

Becton, Dickinson ordered to pay $4.8M in hernia mesh trial – Bloomberg

Aug 29

Becton, Dickinson prices tender offers to buy back debt up to $500M

Aug 23

Becton, Dickinson to market Accelerate Diagnostics' rapid tests for antibiotic resistance

Aug 15

If EPS Growth Is Important To You, Becton Dickinson (NYSE:BDX) Presents An Opportunity

Aug 09
If EPS Growth Is Important To You, Becton Dickinson (NYSE:BDX) Presents An Opportunity

Shareholder Returns

BDXUS Medical EquipmentUS Market
7D-1.7%0.4%2.1%
1Y3.9%13.4%26.0%

Return vs Industry: BDX underperformed the US Medical Equipment industry which returned 13.4% over the past year.

Return vs Market: BDX underperformed the US Market which returned 26% over the past year.

Price Volatility

Is BDX's price volatile compared to industry and market?
BDX volatility
BDX Average Weekly Movement2.5%
Medical Equipment Industry Average Movement8.3%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: BDX has not had significant price volatility in the past 3 months.

Volatility Over Time: BDX's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
189773,000Tom Polenhttps://www.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Becton, Dickinson and Company Fundamentals Summary

How do Becton Dickinson's earnings and revenue compare to its market cap?
BDX fundamental statistics
Market capUS$69.83b
Earnings (TTM)US$1.27b
Revenue (TTM)US$19.49b

55.1x

P/E Ratio

3.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDX income statement (TTM)
RevenueUS$19.49b
Cost of RevenueUS$10.78b
Gross ProfitUS$8.72b
Other ExpensesUS$7.45b
EarningsUS$1.27b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)4.38
Gross Margin44.72%
Net Profit Margin6.49%
Debt/Equity Ratio63.6%

How did BDX perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

84%

Payout Ratio

Does BDX pay a reliable dividends?

See BDX dividend history and benchmarks
When do you need to buy BDX by to receive an upcoming dividend?
Becton Dickinson dividend dates
Ex Dividend DateMar 07 2024
Dividend Pay DateMar 29 2024
Days until Ex dividend7 days
Days until Dividend pay date29 days

Does BDX pay a reliable dividends?

See BDX dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.